Taminadenant mesylate
Based on 1 publication(s) in Google Scholar
Taminadenant mesylate (NIR178 mesylate) is a potent adenosine A2A receptor antagonist with potential anti-tumor activity. Taminadenant mesylate can selectively bind and inhibit A2AR on T lymphocytes, thereby releasing adenosine/A2AR-mediated inhibition of T lymphocytes and activating T cell-mediated immune responses against tumor cells. Taminadenant mesylate works by reducing the proliferation of susceptible tumor cells. Taminadenant mesylate also showed effectiveness in reversing dyskinesias in Parkinson's disease models and was able to inhibit dyskinesias caused by L-DOPA.
For research use only. We do not sell to patients.
- CAS No.: 2253894-81-2
- Formula: C11H12BrN7O3S
- Molecular Weight:402.23
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Taminadenant mesylate
MoreAll Adenosine Receptor Isoforms
More
Biological Activity
Chemical Information
-
CAS No. 2253894-81-2
-
Molecular Weight 402.23
-
Formula C11H12BrN7O3S
-
SMILES
BrC(C(N1C=CC=N1)=NC(N2C=CC=N2)=N3)=C3N.O=S(O)(C)=O
-
Synonyms
NIR178 mesylate; PBF509 mesylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma. [Abstract]2023 Sep 19;4(9):101188. PMID: 37729873
Purity & Documentation
References
[1]. Núñez F, et al. PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders. Front Pharmacol. 2018 Oct 19;9:1200. [Content Brief]
[2]. PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders [Content Brief]
[3]. Chiappori AA, et al. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Jun 1;28(11):2313-2320. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Taminadenant mesylate Related Classifications
HY-109139A Related Classifications
Powered by Bioz